$ASLN Completes Enrolment for Global Pivotal TreeTopp Study investigating varlitinib in secondline biliary tract cancer. Topline data expected in 2H 2019

$ASLN Completes Enrolment for Global Pivotal TreeTopp Study investigating varlitinib in second-line biliary tract cancer. Topline data expected in 2H 2019

05:14 EST 2 Jan 2019 | Odi Bruckman

$ASLN Completes Enrolment for Global Pivotal TreeTopp Study investigating varlitinib in second-line biliary tract cancer. Topline data expected in 2H 2019

More From BioPortfolio on "$ASLN Completes Enrolment for Global Pivotal TreeTopp Study investigating varlitinib in second-line biliary tract cancer. Topline data expected in 2H 2019"